TB-500 (Thymosin Beta-4) vs. IGF-1 LR3

When evaluating TB-500 (Thymosin Beta-4) versus IGF-1 LR3 for biological age reduction, the primary consideration is the specific hallmark of aging being targeted. While both compounds offer systemic healthspan benefits, their mechanisms of action are distinct.

When to prioritize TB-500 (Thymosin Beta-4):

Select TB-500 (Thymosin Beta-4) when the primary clinical objective aligns with its core mechanism: upregulates actin to promote cell migration, angiogenesis, and systemic tissue repair.. This is particularly relevant for protocols focused on systemic tissue regeneration, flexibility support, and wound healing..

When to prioritize IGF-1 LR3:

Conversely, IGF-1 LR3 is the superior choice when targeting modified igf-1 with an arginine substitution and n-terminal extension that reduces igfbp binding, extending half-life and anabolic activity., making it the preferred agent for enhanced anabolic effects and muscle growth with extended half-life..